FDA Inspection 1222301 — Sucampo Pharma, LLC
The FDA completed an inspection of Sucampo Pharma, LLC on September 27, 2023 in Kobe. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 27, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Kobe (Japan)